Semaglutide oral - Novo Nordisk
Alternative Names: GLP-1-SNAC; NN 6535; NN 9932; NN-9924; NNC0113-0217; OG-217SC; Rybelsus; SemagutideLatest Information Update: 02 Oct 2024
At a glance
- Originator Novo Nordisk
- Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase III Alzheimer's disease; Obesity
Most Recent Events
- 23 Aug 2024 Novo Nordisk completes a phase-III clinical trial in Type 2 diabetes mellitus in US, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Hong Kong, India, Japan, Italy, South Korea, Malaysia, Netherlands, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Thailand, Turkey, Ukraine, United Kingdom, Argentina, Colombia, Croatia, Israel, Mexico and Taiwan (PO) (NCT03914326)
- 18 Apr 2024 Novo Nordisk completes a phase I trial in Healthy volunteers in Germany (PO) (NCT05996874) (EudraCT2022-002848-52)
- 29 Mar 2024 Novo Nordisk completes a phase I trial in Healthy volunteers in Canada and USA (PO) (NCT05784402)